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Abstract
Introduction Oxidative stress can modify estrogen receptor
(ER) structure and function, including induction of progesterone
receptor (PR), altering the biology and clinical behavior of
endocrine responsive (ER-positive) breast cancer.
Methods To investigate the impact of oxidative stress on
estrogen/ER-regulated gene expression, RNA was extracted
from ER-positive/PR-positive MCF7 breast cancer cells after 72
hours of estrogen deprivation, small-interfering RNA knockdown
of ER-α, short-term (8 hours) exposure to various oxidant
stresses (diamide, hydrogen peroxide, and menadione), or
simultaneous ER-α knockdown and oxidant stress. RNA
samples were analyzed by high-throughput expression
microarray (Affymetrix), and significance analysis of microarrays
was used to define gene signatures responsive to estrogen/ER
regulation and oxidative stress. To explore the association of
these signatures with breast cancer biology, microarray data
were analyzed from 394 ER-positive primary human breast
cancers pooled from three independent studies. In particular, an
oxidant-sensitive estrogen/ER-responsive gene signature (Ox-
E/ER) was correlated with breast cancer clinical parameters and
disease-specific patient survival (DSS).
Results From 891 estrogen/ER-regulated probes, a core set of
75 probes (62 unique genes) responsive to all three oxidants
were selected (Ox-E/ER signature). Ingenuity pathway analysis
of this signature highlighted networks involved in development,
cancer, and cell motility, with intersecting nodes at growth
factors (platelet-derived growth factor-BB, transforming growth
factor-β), a proinflammatory cytokine (tumor necrosis factor),
and matrix metalloproteinase-2. Evaluation of the 394 ER-
positive primary breast cancers demonstrated that Ox-E/ER
index values correlated negatively with PR mRNA levels (rp = -
0.2; P = 0.00011) and positively with tumor grade (rp = 0.2; P
= 9.741 × e-5), and were significantly higher in ER-positive/PR-
negative versus ER-positive/PR-positive breast cancers (t-test,
P  = 0.0008). Regardless of PR status, the Ox-E/ER index
associated with reduced DSS (n = 201; univariate Cox, P =
0.078) and, using the optimized cut-point, separated ER-
positive cases into two significantly different DSS groups (log
rank, P = 0.0009).
Conclusion An oxidant-sensitive subset of estrogen/ER-
responsive breast cancer genes linked to cell growth and
invasion pathways was identified and associated with loss of PR
and earlier disease-specific mortality, suggesting that oxidative
stress contributes to the development of an aggressive subset
of primary ER-positive breast cancers.
Introduction
Estrogen receptor (ER; α isoform) is a redox-sensitive tran-
scription factor, and breast cancer co-expression of progester-
one receptor (PR) has long been clinically used to signify a
functioning ER response pathway [1] and identify breast can-
cers that are most likely to respond to ER-targeted endocrine
therapy [2-4]. Endocrine therapy, in turn, can alter tumor
expression of ER and PR [5,6]; in particular, upon acquiring
resistance to an endocrine agent such as tamoxifen, meta-
static breast cancers usually retain ER expression [5] but
DMEM = Dulbecco's modified Eagle's medium; DSS = disease-specific survival; ER = estrogen receptor; FWER = family-wise error rate; GSEA = 
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gene signature; PR = progesterone receptor; RFS = relapse-free survival; ROS = reactive oxygen species; siRNA = small-interfering RNA; TNF = 
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frequently exhibit loss of PR expression [6]. At diagnosis, ER-
positive/PR-negative breast cancers appear to be less respon-
sive to endocrine therapy and associated with earlier meta-
static relapse than ER-positive/PR-positive cases [2]. Despite
the clinical biomarker utility of PR in conjunction with ER, fac-
tors that determine the altered biology and more aggressive
clinical nature of ER-positive/PR-negative breast cancers
remain unclear, with aging [7], activated growth factor recep-
tor signaling [8-11], and oxidative stress [7] all implicated in
the loss of PR expression.
As a putative etiologic factor for both aging and age-related
diseases, oxidative stress is an attractive mechanistic hypoth-
esis for the biological heterogeneity of ER-positive breast can-
cers, including PR status. Reactive oxygen species (ROS) are
critical mediators of growth factor receptor signaling [12] and
estrogen-inducible cell proliferation [13,14]. Not only has the
carcinogenic potential of estrogen exposure been attributed to
its oxidation chemistry [15,16], but oxidative stress pathways
activated during cell immortalization and transformation have
been correlated with breast cancer clinical prognosis [17].
Two major cellular consequences of excess oxidant exposure
can specifically influence ER pathways and the endocrine
responsiveness of ER-positive breast cancer. The first of these
is that oxidative stress can reversibly or irreversibly directly
alter protein structure. Among intracellular proteins most sen-
sitive to oxidant-induced structural and functional damage are
redox-sensitive zinc finger transcription factors such as ER
[18] and Sp1 [19], whose zinc finger cysteine residues are
readily oxidized, eliminating their DNA-binding activity. In ER-
positive breast cancers, loss of Sp1 DNA binding activity has
been correlated with aging in association with increased tumor
content of the oxidative stress marker P-Erk5 [7]. Although not
necessarily associated with aging, loss of ER DNA-binding
activity has been found in up to one-third of all ER-positive
breast cancers and correlated with loss of PR expression [20].
Because both ER-α and Sp1 DNA-binding and transactivating
functions are needed for optimal estrogenic stimulation of
genes such as PR and Bcl2, ER-positive breast cancers sub-
jected to sufficient oxidative stress would be expected to
exhibit suppressed expression of these estrogen-inducible
genes.
A second major consequence of oxidative stress is its associ-
ation with kinase-dependent signaling pathways. Aside from
mediating growth factor receptor signaling, ROS directly
inhibit protein tyrosine phosphatases and enhance Src, c-Jun
amino-terminal kinase (JAK), Ras, protein kinase C (PKC), and
mitogen-activated protein kinase (MAPK) signal transduction
[21]. These activated kinase pathways also modulate ER sig-
naling [22] and have been implicated in endocrine resistance
[23-26]. In experimental models, excess MAPK signaling has
been shown to repress ER expression and impair estrogen-
inducible gene transcription [27]; and expression microarray
analyses have shown that activation of MAPK signaling in cul-
tured ER-positive breast cancer cells induces a profile of gene
expression similar to that of ER-negative breast cancer [28].
Thus, ROS-activated kinases represent another means by
which ER function can be compromised after oxidant stress
and potentially associated with the clinical phenotype of ER-
positive/PR-negative breast cancer.
Although gene expression profiles signifying estrogen respon-
siveness [29] and oxidative stress [30] have been independ-
ently identified from studies of ER-positive breast cancer cell
line models, altered ER-regulated gene expression within the
context of oxidative stress has not yet been addressed. Like-
wise, models simulating loss of estrogen-induced gene
expression, as expected with aging and menopause, in con-
trast to estrogen-stimulated gene expression, have not been
experimentally explored. In the present study, both estrogen
deprivation and small-interfering RNA (siRNA) knockdown of
ER-α are utilized to identify a complete set of estrogen/ER-
regulated genes from which a subset responsive to all three
forms of oxidant stress (diamide, hydrogen peroxide, and
menadione) are derived as an oxidant-sensitive estrogen/ER
gene signature (Ox-E/ER). Also, oxidant-sensitive genes
experimentally determined following ER knockdown are ana-
lyzed in relation to estrogen/ER-regulated genes to derive an
alternative Ox-E/ER signature (Ox'-E/ER). The relationships of
these indicators of oxidant exposure, in particular the Ox-E/ER
gene signature, to breast cancer biology and clinical outcome
are further explored using microarray data from 394 ER-posi-
tive primary human breast cancers pooled from three inde-
pendently published studies.
Materials and methods
Cells, culture treatments, and RNA extraction
ER-positive/PR-positive MCF7 human breast cancer cells
were obtained from the American Type Culture Collection
(Rockville, MD, USA). Cells were routinely maintained at 37°C
and 5% carbon dioxide in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum,
1% penicillin-streptomycin, and 10 ng/ml insulin. Media and
supplements were purchased from Mediatech, Inc. (Herndon,
MA, USA). For ER-α knockdown, MCF7 cells were trans-
fected with 100 nmol/l anti-ER-α siRNA (Dharmacon, IL, USA)
using Lipofectamine-2000 (Invitrogen, CA, USA), in accord-
ance with the manufacturer's protocol, and incubated for 72
hours. For estrogen deprivation, cells were plated in DMEM
and allowed to attach overnight. The media were then
changed to DMEM without phenol red; supplemented with
10% charcoal-stripped fetal bovine serum, 1% penicillin-
streptomycin, and 10 ng/ml insulin; and cultures were incu-
bated for an additional 72 hours. For oxidant treatments,
MCF7 cells were treated with 275 nmol/l diamide or 0.5
mmol/l hydrogen peroxide (H2O2) or 10 μmol/l menadione for
8 hours. These oxidant doses and exposure times were cho-
sen for their ability to significantly impair ER transcriptionalAvailable online http://breast-cancer-research.com/content/10/4/R61
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activation without significantly impairing total ER content and
cell viability (Additional file 1). Diamide and menadione were
purchased from Sigma (Louisville, MO, USA) and H2O2 was
obtained from VWR International (West Chester, PA, USA).
For simultaneous ER-α knockdown and oxidant stress, MCF7
cells were transfected with 100 nmol/l anti-ER-α siRNA (Dhar-
macon, IL, USA) using Lipofectamine-2000 (Invitrogen, CA,
USA), in accordance with the manufacturer's protocol, and
incubated for 64 hours before oxidant treatment (275 nmol/l
diamide or 0.5 mmol/l H2O2 or 10 μmol/l menadione) for 8
hours. All treatments were performed in duplicate. Total cell
RNA was extracted using RNeasy Mini Kit in accordance with
the manufacturer's instruction (Qiagen, CA, USA). RNA was
diluted to 0.4 μg/μl, and RNA integrity was assayed using a
2100 Bioanalyzer (Agilent, CA, USA).
Microarray analysis and gene signature derivations
Total RNA (4 μg per MCF7 sample) was labeled and analyzed
using Affymetrix, Inc. (Santa Clara, CA, USA) HT-HG_U133A
Early Access Arrays containing 22.9 K probes representing
about 13 K unique Unigenes. Analyses were performed by
standard Affymetrix procedures within the Lawrence Berkeley
National Laboratory and Life Science Divison's Molecular Pro-
filing Laboratory. Probe set measurements were generated
from quantified Affymetrix image (.CEL) files using the RMA
algorithm in Bioconductor R [31]. MCF7 microarray data were
deposited into the public Gene Expression Omnibus database
(GSE10061). Significance analysis of microarrays software
[32] was used to determine significant changes in gene
expression between treated and corresponding reference
samples (control MCF7 for the single agent treatments, and
ER-α knockdown MCF7 for the combined knockdown and oxi-
dant stress treatment conditions). Venn diagrams were con-
structed in Bioconductor R, and the overlapping probes
between treatment conditions were used to define the follow-
ing gene signatures: estrogen/ER genes (overlapping probes
from estrogen deprivation and ER-α siRNA treatment), Ox
genes (probes commonly affected by all three oxidant stresses
in control MCF7), Ox' genes (probes commonly affected by all
three oxidant stresses after ER-α knockdown in MCF7), Ox-E/
ER genes (estrogen/ER genes responsive to all three oxidant
stresses in control MCF7), and Ox'-E/ER genes (estrogen/ER
genes responsive to all three oxidant stresses following ER-α
knockdown).
Gene signatures and clinical parameters for 394 
estrogen receptor positive primary breast tumors
Our own tumor dataset consisted of 102 early-stage age-
stratified ER-positive primary breast cancer samples; these
samples were obtained following multi-institutional review
board approval and all information pertaining to these sam-
ples, their RNA processing, and microarray analysis has previ-
ously been reported [33], with primary data deposited into the
Gene Expression Omnibus database (GSE7378 and
GSE8193). Two other publicly available datasets were also
used in this analysis: 214 ER-positive cases were selected
from the study conducted by Miller and coworkers [34], and
79 ER-positive cases were selected from the study conducted
by Hess and colleagues [35], resulting in a pooled set of 394
ER-positive primary breast tumors. Although treatment data
were not available for all samples, more than 50% of these
394 cases received adjuvant systemic therapy. Because all
three microarray studies used similar Affymetrix U133A plat-
forms, all probe set measurements were generated using the
RMA algorithm in Bioconductor R and related by Affymetrix
probe identifiers. Individual datasets were mean-centered, and
in order to remove possible systematic biases based on data
source, distance-weighted discrimination [36] (DWD) was
applied. ERBB2 status was reported for 181 cases in the
pooled 394 ER-positive breast cancer dataset. An expression
array cut-off value for ERBB2 probe 216836_s_at, previously
shown to accurately reflect clinical ERBB2 status [37], was
determined by minimizing misclassification error among the
181 samples with known ERBB2 status; and the remaining
213 cases were assigned ERBB2 status based on the expres-
sion array cut-off value.
Gene set enrichment analysis (GSEA) was performed using
GSEA software version 2.1 [38] to assess all gene signatures
with respect to clinical parameters. Ranking of genes with
respect to categorical tumor phenotypes such as PR status,
expression array determined ERBB2 status, nodal status, and
grade was based on the signal-to-noise metric; and Pearson
correlation was used to rank-order genes with respect to age
at diagnosis. For genes with multiple probes, the median value
from all expressed probes was used. Each gene signature
enrichment score was derived as a function of the likelihood of
that signature set being among the most highly ranked genes
for each tumor phenotype, and enrichment score significance
was estimated using 1,000 random permutations of the sam-
ple labels in the tumor dataset. For comparison, enrichment of
four other reported gene signatures was also assessed; these
included MAPK [28], proliferation [39], luminal [40], and sus-
tained estrogen-induced [29] gene signatures, as listed in
Additional file 2. To explore the relationship between oxidative
stress and proliferation, hierarchical clustering of the com-
bined dataset was performed based on expression of the pro-
liferation signature [39] using Cluster software [41] and
visualized with Java TreeView [42]. The dataset was dichot-
omized into tumors with higher proliferation signature (H) and
tumors with lower proliferation signature (L). Numeric indices
were calculated for the Ox, Ox', Ox-E/ER and Ox'-E/ER signa-
tures as follows:
Where x is the DWD-transformed expression measure, j is a
gene indicator, ∈ signifies 'contained in', and U and D are the
set of probes upregulated and downregulated by oxidative
I n d e x xn xm j
jU
j
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stress, respectively. A two-sample t-test with unequal variance
was used to compare index values for each signature with
respect to tumor proliferation status (H, L).
Ox-E/ER gene signature functional analysis and 
prognostic validation
Ingenuity pathway analysis software (Ingenuity Systems Inc.,
Mountain View, CA, USA) was used to identify top biological
networks represented by the Ox-E/ER gene signature. A two-
sample t-test with unequal variance was used to compare Ox-
E/ER index values with respect to PR status, array determined
ERBB2 status, grade, and nodal status. Pearson correlations
were determined between the index and PR mRNA expression
level as well as each clinical parameter (age, array determined
ERBB2 status, grade and nodal status). The pooled tumor
sample set contained 201 cases with disease-specific survival
(DSS) information (>33% adjuvant treated), and 263 cases
with relapse-free survival (RFS) information (>46% adjuvant
treated); and the prognostic value of the gene signature index
was evaluated by univariate Cox analysis. Univariate Cox anal-
yses based on patient age, tumor PR status, PR mRNA level,
nodal status, and grade were also performed. Multivariate Cox
analysis was used to determine which of these variables dem-
onstrated independent prognostic significance. For the 201
cases with DSS data, an optimized cut-point for the Ox-E/ER
gene signature index was determined using a modified log-
rank statistic [43]. Kaplan-Meier analyses were performed on
this dataset dichotomized by the optimized index cut-point and
compared with the same data dichotomized by PR status.
Results
Defining gene signatures responsive to estrogen/
estrogen receptor modulation and oxidative stress
As shown in Figure 1, differential expression analysis identified
2,640 probes as estrogen responsive, based on 72 hours of
MCF7 E deprivation (1.5× fold change, false discovery rate q
= 0.01); similarly, 1,056 differentially expressed probes were
considered to be ER regulated, based on 72 hours of knock-
Figure 1
Experimental conditions and derivation of gene signatures based on MCF7 treatments and microarray analyses Experimental conditions and derivation of gene signatures based on MCF7 treatments and microarray analyses. Depicted by the left set of condi-
tions, the Ox' gene signature (color-coded in gold) was derived as the overlapping probe set after significance analysis of microarrays (SAM) com-
parisons of expression microarrays results from MCF7 treated with both estrogen receptor (ER)-α small-interfering RNA (siRNA) and oxidants, 
relative to MCF7 treated only with ER-α siRNA. Depicted by the middle set of conditions, the estrogen (E)/ER gene signature (color-coded in blue) 
was derived as the overlapping set of differentially expressed MCF7 probes following estradiol (E2) deprivation and ER-α knockdown. Depicted by 
the right set of conditions, the Ox signature (color-coded yellow) was derived as the overlapping probe set after SAM comparisons of microarray 
results from oxidant stressed MCF7 relative to control MCF7. The overlap between the Ox' and E/ER signatures defines the Ox'-E/ER signature 
(color-coded dark green); and the overlap between the Ox and E/ER signatures defines the Ox-E/ER gene signature (color-coded light green).Available online http://breast-cancer-research.com/content/10/4/R61
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down of ER-α in MCF7 by siRNA. Altogether, an overlapping
set of 891 probes was identified as estrogen/ER responsive
and evaluated further with respect to their oxidant sensitivity
(Figure 1).
Relative to a recent microarray study of estrogen-treated
MCF7 [29], only 31% of these 891 probes presently identified
as responsive to either estrogen deprivation or ER-α knock-
down are also stimulated by estrogen treatment of MCF7
cells. With regard to MCF7 oxidant sensitivity, Figure 1 shows
that 283 probes were identified as differentially expressed
after 8 hours of diamide treatment, whereas 1,184 and 1,155
probes exhibited significant changes in expression after 8
hours of treatment with H2O2 or menadione, respectively. Alto-
gether, 1,750 probes exhibited some oxidant sensitivity, and
182 probes commonly affected by all three oxidants defined
the Ox gene signature (Figure 1). Of these, a set of 75 probes
(62 unique genes) commonly affected by all oxidants and rep-
resenting only 8% of all E/ER responsive probes defined the
Ox-E/ER gene signature (Figure 1). Within this Ox-E/ER gene
signature is the well characterized estrogen responsive gene
Bcl2. PR and GREB1, two genes commonly associated with
estrogen responsiveness in breast cancer, are not included in
the signature because their expression levels were signifi-
cantly reduced by H2O2 and menadione treatments but not
significantly reduced by the thiol-specific oxidant diamide. Fol-
lowing ER-α knockdown in MCF7, expression of 333 probes
was subsequently altered by 8 hours of diamide, whereas lev-
els of 720 and 1,518 probes were subsequently altered by
H2O2  or menadione treatments, respectively (Figure 1).
Among the total 1,740 oxidant affected probes in MCF7 with
downregulated ER-α, 223 were commonly affected and
defined the Ox' gene signature (Figure 1). Among this Ox'
gene signature are 84 estrogen/ER-responsive probes, which
defined the Ox'-E/ER gene signature (Figure 1). There is a 33-
probe overlap (25 unique genes) between the Ox-E/ER and
Ox'-E/ER gene signatures. Genes responsive to each of the
eight different treatment conditions schematically illustrated in
Figure 1 are fully listed in Additional file 3.
Gene signature enrichment and estrogen receptor-
positive breast cancer clinical features
The pooled clinical dataset of 394 ER-positive primary breast
cancers were subjected to GSEA to identify clinical parame-
ters (patient age at diagnosis, tumor grade, PR, ERBB2, and
nodal status) potentially associated with the five derived gene
signatures, as well as previously reported gene signatures rep-
resenting sustained estrogen induction [29], luminal subtype
[40], MAPK activation [28], and tumor proliferation [39]. The
results of these analyses are summarized in Tables 1 and 2,
and include values for the normalized enrichment score, nom-
inal and adjusted (family-wise error rate [FWER]) P values.
The luminal signature, as well as the Ox, Ox', and Ox-E/ER
genes repressed by oxidant stress, showed nominal enrich-
ment in ER-positive/PR-positive tumors (or suppression in ER-
positive/PR-negative tumors), whereas the proliferation signa-
ture showed nominal enrichment in ER-positive/PR-negative
tumors (P  < 0.05). However, after adjustment for multiple
gene set testing, only enrichment of the proliferation signature
in ER-positive/PR-negative primary breast cancers retained
significance (FWER, P = 0.01). A strong trend was observed
for enrichment of oxidant-repressed Ox-E/ER genes (such as
Bcl2) in ER-positive/PR-positive tumors, reflecting their sup-
pression in ER-positive/PR-negative tumors (FWER, P  =
0.07). Also, the proliferation signature, along with the Ox and
Ox' genes induced by oxidative stress, exhibited nominal
enrichment in ERBB2 over-expressing tumors, whereas the
luminal signature was nominally enriched in ERBB2-negative
tumors (P < 0.05). However, after multiple gene set testing,
only enrichment of the proliferation signature retained
significance in the ERBB2 over-expressing tumors (FWER, P
= 0.01).
With regard to breast cancer age at diagnosis, GSEA indi-
cated that estrogen/ER-repressed genes were positively cor-
related whereas estrogen/ER-stimulated genes were
negatively correlated with older age at diagnosis (nominal P <
0.05), a finding consistent with the previously reported loss of
estrogen-induced gene expression in ER-positive breast can-
cers arising later in life [29]. Also consistent with previous age-
linked breast cancer features [33] was the observed negative
correlation between the proliferation signature and zincreasing
age at diagnosis (Table 1) and the enriched expression of lumi-
nal signature in ER-positive breast cancers arising later in life
(nominal P < 0.05). The repressed Ox' genes (suggesting
decreased oxidative stress) also appeared to be enriched
among tumors arising later in life (nominal P < 0.05); and con-
sistent with this observation was the trend for Ox and Ox-E/ER
genes induced by oxidative stress to exhibit lower expression
with increasing age at diagnosis (nominal P = 0.07 and 0.09,
respectively). After correcting for multiple gene-set testing,
however, only the association between the luminal signature
and older age at diagnosis retained significance (FWER, P =
0.01).
Among the 15 gene sets analyzed in Table 2, only the prolifer-
ation signature showed significant enrichment with respect to
regional lymph node involvement, with node-positive tumors
showing significantly higher expression of the proliferation
markers (nominal P = 0.008; FWER, P = 0.02). There was
also significant enrichment of the proliferation signature with
ER-positive tumors of increasing grade in all pair-wise compar-
isons. In contrast, luminal markers were nominally enriched in
grade 1 and 2 tumors over grade 3 tumors, whereas the pre-
viously reported estrogen-induced gene signature was
enriched in grade 2 and 3 tumors over their grade 1 counter-
parts. There was also increased enrichment of Ox and Ox'
repressed gene expression in grade 2 over grade 3 tumors
(nominal P = 0.03 and 0.01, respectively), and Ox' repressedBreast Cancer Research    Vol 10 No 4    Yau and Benz 
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gene expression was nominally higher in grade 1 over grade 3
tumors, with reciprocal enrichment of Ox' induced genes in
grade 3 over grade 1 tumors. No significant associations with
respect to tumor grade were observed in other pair-wise com-
parisons; in particular, the Ox-E/ER signature did not show any
significant grade-associated enrichment.
Oxidative stress associations with tumor proliferation
Indices determined from each of the Ox, Ox', Ox-E/ER, and
Ox'-E/ER signatures were correlated with ER-positive tumor
proliferation status. As shown in Figure 2a, when proliferation
markers [39] were used to perform unsupervised hierarchical
clustering of the 394 pooled ER-positive breast cancer cases,
two comparably sized subsets were identified (H, L). The sub-
set with higher (H) expression of proliferation genes was asso-
ciated with significantly higher Ox, Ox', and Ox-E/ER indices
(t-test, P < 0.05) relative to the subset with lower (L) expres-
sion of proliferation genes (Figure 2b); the trend for H tumors
to have a higher Ox'-E/ER index did not quite reach statistical
significance (P = 0.07). These positive correlations were in
keeping with the GSEA findings in which tumor phenotypes
associated with oxidant-responsive gene sets were also simi-
larly associated with proliferation gene expression.
Pathway analysis of the Ox-E/ER gene signature
The Ox-E/ER gene signature (Table 3) was selected for further
functional annotation and prognostic validation based on its
robust correlation with clinical PR status and tumor prolifera-
tion. Pathway analysis was performed using Ingenuity Pathway
Systems, which identified three top networks represented
within the 62-gene Ox-E/ER signature. The highest scoring
network related to cancer, cell growth, and death, linking 19
Ox-E/ER genes to well defined oxidative stress response path-
ways such as nuclear factor-κB and c-Jun amino-terminal
kinase activation (Figure 3a). Coordinate expression of nine
Ox-E/ER genes known to vary in response to platelet-derived
growth factor-BB and transforming growth factor-β implicated
activated signal transduction d o w n s t r e a m  f r o m  t h e s e  t w o
breast cancer growth factors. A second network related to
cancer and cellular development linked 17 members of this
Table 1
Gene set enrichment analysis of 394 ER-positive breast cancers: part 1
Comparison
PR- over PR+ ERBB2- over ERBB2+ Age
Gene set NES Nominal P FWER P NES Nominal P FWER P NES Nominal P FWER P
Modulation of E2 and 
ER
Estrogen/ER induced -1.03 0.42 0.91 1.06 0.36 0.87 -1.60 0.02 0.18
Estrogen/ER 
repressed
-1.14 0.27 0.81 -0.99 0.46 0.90 1.67 0.01 0.11
Modulation of oxidative 
stress
Ox induced 1.15 0.28 0.78 -1.61 0.04 0.19 -1.45 0.07 0.36
Ox repressed -1.53 0.02 0.24 1.19 0.20 0.75 1.18 0.21 0.74
Ox-E/ER Ox-induced 0.90 0.54 0.95 -1.43 0.11 0.40 -1.45 0.09 0.37
Ox-E/ER Ox repressed -1.75 0.00 0.07 1.36 0.11 0.53 -1.13 0.29 0.81
Modulation of ER and 
oxidative stress
Ox' induced 1.17 0.24 0.75 -1.66 0.02 0.13 -1.21 0.19 0.71
Ox' repressed -1.54 0.04 0.23 1.21 0.21 0.73 1.71 0.01 0.09
Ox'-E/ER Ox induced -1.30 0.15 0.61 -1.04 0.40 0.86 -1.19 0.24 0.75
Ox'-E/ER Ox 
repressed
-1.39 0.11 0.44 0.94 0.54 0.93 1.49 0.07 0.32
Literaturea MAPK induced 1.16 0.28 0.77 -0.98 0.48 0.91 -0.74 0.78 0.98
MAPK repressed -1.17 0.25 0.77 1.09 0.33 0.83 0.99 0.46 0.92
Luminal markers -1.69 0.03 0.10 1.68 0.02 0.11 1.85 0.00 0.01
Sustained estrogen-
induced
1.00 0.45 0.90 -1.26 0.18 0.64 -1.07 0.36 0.85
Proliferation markers 1.92 0.00 0.01 -1.95 0.00 0.01 -1.70 0.04 0.09
Gene sets showing nominal enrichment (P < 0.05) are denoted in bold. aMitogen-activated protein kinase (MAPK) [42], luminal [54], sustained 
estrogen-induced [43], and proliferation signatures [53] as shown in Additional file 2. E2, estradiol; ER, estrogen receptor; FWER, family-wise 
error rate; NES, normalized enrichment score; Ox-E/ER, oxidant-sensitive estrogen/ER gene signature; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/10/4/R61
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signature to tumor necrosis factor (TNF)-α and estrogen (Fig-
ure 3b). The coordinate pattern of expression of eight known
TNF-α responsive Ox-E/ER genes reflects downstream
effects from this breast cancer cytokine; however, the four
estrogen-linked genes did not show coordinate expression
consistent with decreased estrogen signaling. A third network
linked 12 members of the Ox-E/ER gene signature with cell
motility (Figure 3c). Connection nodes of interest included β-
catenin (CTNNB1) and matrix metalloproteinase (MMP)2,
both of which have previously been correlated to metastasis in
various cancers. In particular, increased MMP2 activity has
been implicated through direct upregulation by the Ox-E/ER
gene CLDN1 [44]. Possible mechanisms connecting altera-
tions in normal β-catenin function through oxidant downregu-
lation of MACF1[45] and CDH18 [46] are also suggested.
Numeric Ox-E/ER index, tumor progesterone status, and 
clinical outcome
A numeric index calculated from the Ox-E/ER gene expression
signature was found to correlate significantly with clinical PR
status in the 394 ER-positive primary breast cancers (t-test, P
= 0.0008). The Ox-E/ER signature index was 1.2-fold higher
in ER-positive/PR-negative tumors relative to ER-positive/PR-
positive tumors and, as shown in Figure 4a, exhibited a signif-
icant inverse correlation with PR gene transcript levels (rp = -
0.19; P = 0.0001). For comparison, the positive correlation
observed between clinical PR status and array determined PR
transcript levels from this same dataset was of comparable,
albeit slightly greater, magnitude (rp = +0.24; P = 9.033 × e-
07). In keeping with the GSEA findings, no significant associa-
tions were observed between the numeric Ox-E/ER index and
age at diagnosis (Figure 4b). Although GSEA failed to detect
any significant enrichment of the Ox-E/ER signature genes in
Table 2
Gene set enrichment analysis of 394 ER-positive breast cancers: part 2
Comparison
LN- over LN+ Grade 3 over grade 1 Grade 3 over grade 2 Grade 2 over grade 1
Gene set NES Nominal P FWER P NES Nominal P FWER P NES Nominal P FWER P NES Nominal P FWER P
Modulation of E2 
and ER
Estrogen/ER 
induced
-1.38 0.07 0.47 1.40 0.07 0.45 1.14 0.27 0.78 1.27 0.15 0.63
Estrogen/ER 
repressed
1.35 0.11 0.52 -1.51 0.05 0.28 -1.27 0.16 0.62 -1.21 0.18 0.69
Modulation of 
oxidative stress
Ox induced 1.14 0.30 0.79 1.44 0.08 0.38 1.55 0.06 0.23 0.78 0.75 0.98
Ox repressed 1.03 0.42 0.87 -1.32 0.11 0.57 -1.51 0.03 0.29 -0.88 0.65 0.95
Ox-E/ER Ox 
induced
1.10 0.36 0.82 1.11 0.34 0.80 1.11 0.35 0.82 -0.98 0.46 0.90
Ox-E/ER Ox 
repressed
1.24 0.20 0.69 -1.00 0.44 0.90 -1.34 0.12 0.54 -0.42 1.00 1.00
Modulation of 
ER and oxidative 
stress
Ox' induced 1.00 0.44 0.89 1.50 0.05 0.30 1.53 0.06 0.25 0.82 0.70 0.97
Ox' repressed 0.99 0.47 0.90 -1.74 0.01 0.06 -1.70 0.01 0.09 -1.19 0.21 0.73
Ox'-E/ER Ox 
induced
1.03 0.42 0.87 0.91 0.52 0.93 0.75 0.77 0.98 -1.43 0.12 0.40
Ox'-E/ER Ox 
repressed
1.24 0.20 0.68 -1.65 0.02 0.12 -1.35 0.13 0.53 -1.48 0.06 0.32
Literaturea MAPK induced 0.99 0.45 0.90 0.81 0.70 0.98 0.95 0.52 0.92 -0.55 0.96 1.00
MAPK 
repressed
-1.09 0.31 0.81 1.06 0.38 0.84 -1.02 0.44 0.88 1.17 0.27 0.75
Luminal markers 1.19 0.32 0.73 -1.71 0.02 0.08 -1.77 0.01 0.05 -0.81 0.65 0.97
Sustained 
estrogen-
induced
-1.20 0.23 0.69 1.79 0.00 0.03 1.33 0.11 0.54 1.63 0.02 0.14
Proliferation 
markers
-1.76 0.02 0.06 2.02 0.00 0.00 1.97 0.00 0.00 1.90 0.00 0.01
Gene sets showing nominal enrichment (p < 0.05) are denoted in bold.
Gene sets showing nominal enrichment (P < 0.05) are denoted in bold. aMitogen-activated protein kinase (MAPK) [42], luminal [54], sustained estrogen-induced [43], 
and proliferation signatures [53] as shown in Additional file 2. E2, estradiol; ER, estrogen receptor; FWER, family-wise error rate; LN, lymph node; NES, normalized 
enrichment score; Ox-E/ER, oxidant-sensitive estrogen/ER gene signature; PR, progesterone receptor.Breast Cancer Research    Vol 10 No 4    Yau and Benz 
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ER-positive tumors according to clinical grade, Figure 4c dem-
onstrates that a higher numeric Ox-E/ER signature index cor-
relates significantly with higher tumor grade (rp = 0.20; P =
9.741 × e-05), with grade 3 tumors showing an approximately
1.2-fold higher Ox-E/ER index relative to lower grade tumors
(t-test, P = 0.0002 against grade 1 and P = 0.001 against
grade 2). Also, Figure 4d shows a significant positive correla-
tion between the Ox-E/ER index and array determined ERBB2
over-expression (rp = 0.23; P = 3.66 × e-06), with ERBB2 over-
expressing tumors exhibiting an approximately 1.3-fold higher
Ox-E/ER index than ERBB2-negative tumors.
Univariate Cox analysis was performed to assess the prognos-
tic value of the numeric Ox-E/ER index in comparison with PR
gene expression levels and commonly accepted clinical prog-
nostic parameters including patient age, tumor grade, PR, and
nodal status. Except for patient age, the other known prognos-
tic parameters significantly associated with both RFS and
DSS. PR expression levels and the Ox-E/ER index both
showed strong prognostic trends, with higher PR expression
associated with better DSS (P = 0.056) and higher Ox-E/ER
index tumors associated with worse DSS (P = 0.07). Follow-
ing multivariate Cox analysis, only nodal status retained signif-
icance as an independent predictor of either RFS or DSS in
this dataset. Restricting further outcome analysis to DSS, an
optimized numeric cut-point of 0.3 was defined for the Ox-E/
ER index using a modified log-rank statistic. As shown in Fig-
ure 5a, this index cut-point dichotomized the 201 ER-positive
tumors with DSS data into two different prognostic sub-
groups: 53 tumors with higher index values and worse DSS,
and 148 tumors with lower Ox-E/ER index values and better
DSS (log-rank, P = 0.000911). Using this optimized cut-point
Figure 2
Relationship between oxidative stress and ER-positive tumor proliferation Relationship between oxidative stress and ER-positive tumor proliferation. (a) Unsupervised clustering of 394 estrogen receptor (ER)-positive breast 
cancers based only on expression of the 71-gene proliferation signature, revealing two major clusters of tumors showing high (H) and low (L) expres-
sion of the proliferation genes. (b) Box plots showing the expression indices determined for each of the Ox, Ox', Ox-E/ER, and Ox'-E/ER signatures 
in tumors identified from (panel a) as having either high (H) or low (L) expression of the proliferation genes. *Statistically significant difference in 
mean expression index (t-test P < 0.05). Ox-E/ER, oxidant-sensitive estrogen/ER gene signature.Available online http://breast-cancer-research.com/content/10/4/R61
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Figure 3
Pathway analysis of the Ox-E/ER gene signature Pathway analysis of the Ox-E/ER gene signature. (a) Top scoring gene network represented in the Ox-E/ER gene signature. Ox-E/ER genes upreg-
ulated by oxidative stress are colored in red, and oxidative stress downregulated genes are colored in blue. Intensity of color reflects the magnitude 
of the average fold changes across the three oxidants as listed below the gene. Uncolored nodes are added by the Ingenuity Pathway Systems soft-
ware, and are not present in the Ox-E/ER signature. Solid lines signify direct gene-gene interactions, whereas broken lines represent indirect rela-
tionships that may require secondary effectors not depicted in the network. All connections are supported by at least one published report or from 
canonical information stored in the Ingenuity Pathway Knowledge Base. (b) Number 2 scoring network represented in the Ox-E/ER gene signature. 
(c) Third top scoring network represented in the Ox-E/ER gene signature. ER, estrogen receptor; Ox-E/ER, oxidant-sensitive estrogen/ER gene 
signature.Breast Cancer Research    Vol 10 No 4    Yau and Benz 
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Table 3
Ox-E/ER gene signature
Affymetrix probe 
set ID
UniGene symbol E/ER sensitivity Oxidant 
sensitivity
Fold change
E deprivation ER-α 
knockdown
8 hours diamide 8 hours H2O2 8 hours 
menadione
213245_at ADCY1 E/ER Induced Repressed 0.38 0.46 0.56 0.36 0.57
212136_at ATP2B4 E/ER Induced Repressed 0.54 0.52 0.53 0.50 0.55
203685_at BCL2 E/ER Induced Repressed 0.25 0.39 0.66 0.43 0.56
213605_s_at C6orf216 E/ER Induced Repressed 0.47 0.48 0.53 0.63 0.60
219174_at CCDC2 E/ER Induced Repressed 0.49 0.66 0.64 0.61 0.47
206280_at CDH18 E/ER Induced Repressed 0.37 0.49 0.45 0.37 0.36
204135_at DOC1 E/ER Induced Repressed 0.48 0.50 0.46 0.51 0.26
214240_at GAL E/ER Induced Induced 0.27 0.42 1.84 1.82 2.04
210640_s_at GPR30 E/ER Induced Repressed 0.19 0.60 0.46 0.36 0.27
211829_s_at GPR30 E/ER Induced Repressed 0.29 0.44 0.43 0.35 0.33
204237_at GULP1 E/ER Induced Repressed 0.44 0.56 0.65 0.62 0.49
204235_s_at GULP1 E/ER Induced Repressed 0.46 0.64 0.64 0.60 0.48
215913_s_at GULP1 E/ER Induced Repressed 0.50 0.64 0.61 0.59 0.53
207719_x_at KIAA0470 E/ER Induced Repressed 0.59 0.63 0.57 0.61 0.58
207358_x_at MACF1 E/ER Induced Repressed 0.52 0.51 0.66 0.61 0.61
203037_s_at MTSS1 E/ER Induced Repressed 0.50 0.63 0.59 0.39 0.32
214156_at MYRIP E/ER Induced Repressed 0.40 0.51 0.48 0.38 0.36
212462_at MYST4 E/ER Induced Repressed 0.52 0.53 0.63 0.66 0.36
215643_at SEMA3D E/ER Induced Repressed 0.36 0.39 0.51 0.35 0.39
220038_at SGK3 E/ER Induced Repressed 0.15 0.34 0.61 0.32 0.32
207586_at SHH E/ER Induced Repressed 0.16 0.32 0.59 0.53 0.37
216504_s_at SLC39A8 E/ER Induced Repressed 0.37 0.55 0.66 0.49 0.61
209921_at SLC7A11 E/ER Induced Induced 0.37 0.38 1.68 11.09 8.82
217678_at SLC7A11 E/ER Induced Induced 0.37 0.52 2.18 13.46 11.81
201195_s_at SLC7A5 E/ER Induced Induced 0.35 0.51 1.60 1.72 1.78
212353_at SULF1 E/ER Induced Repressed 0.36 0.45 0.52 0.44 0.46
203998_s_at SYT1 E/ER Induced Repressed 0.57 0.54 0.52 0.53 0.49
208161_s_at ABCC3 E/ER Repressed Induced 7.30 4.63 1.78 2.29 3.11
209641_s_at ABCC3 E/ER Repressed Induced 7.91 3.94 1.79 2.50 3.46
203196_at ABCC4 E/ER Repressed Induced 3.08 4.16 1.93 1.93 2.31
206561_s_at AKR1B10 E/ER Repressed Induced 2.93 3.00 3.26 5.25 9.07
203180_at ALDH1A3 E/ER Repressed Induced 9.43 8.26 3.07 5.80 6.94
205965_at BATF E/ER Repressed Induced 2.35 2.02 1.51 1.98 2.07
207996_s_at C18orf1 E/ER Repressed Repressed 5.71 2.07 0.49 0.36 0.47
213618_at CENTD1 E/ER Repressed Induced 3.27 2.17 1.65 2.18 3.28
218182_s_at CLDN1 E/ER Repressed Induced 2.48 2.64 2.77 5.43 5.28
221059_s_at COTL1 E/ER Repressed Induced 2.45 1.81 1.56 1.59 1.82
209101_at CTGF E/ER Repressed Induced 8.30 4.15 1.78 3.68 15.15
217028_at CXCR4 E/ER Repressed Repressed 3.22 2.82 0.47 0.56 0.30Available online http://breast-cancer-research.com/content/10/4/R61
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205749_at CYP1A1 E/ER Repressed Induced 3.28 0.55 6.75 8.96 33.02
210757_x_at DAB2 E/ER Repressed Repressed 3.25 1.51 0.51 0.60 0.43
201279_s_at DAB2 E/ER Repressed Repressed 3.45 1.67 0.47 0.56 0.39
201278_at DAB2 E/ER Repressed Repressed 4.26 1.99 0.47 0.53 0.45
201280_s_at DAB2 E/ER Repressed Repressed 4.89 2.30 0.42 0.42 0.32
201694_s_at EGR1 E/ER Repressed Induced 5.77 4.42 1.73 3.03 2.52
219850_s_at EHF E/ER Repressed Repressed 4.14 3.96 0.43 0.35 0.35
220625_s_at ELF5 E/ER Repressed Repressed 2.27 2.12 0.49 0.53 0.39
220624_s_at ELF5 E/ER Repressed Repressed 2.38 2.35 0.54 0.53 0.38
201324_at EMP1 E/ER Repressed Induced 15.49 8.23 1.55 1.80 2.49
202949_s_at FHL2 E/ER Repressed Induced 1.63 1.56 2.15 3.87 5.07
213144_at GOSR2 E/ER Repressed Induced 1.81 1.86 1.93 1.95 1.72
212444_at GPCR5A E/ER Repressed Induced 3.73 2.33 1.51 2.51 1.65
203108_at GPRC5A E/ER Repressed Induced 2.46 2.07 1.57 2.58 1.70
203424_s_at IGFBP5 E/ER Repressed Repressed 2.81 1.99 0.52 0.48 0.47
211959_at IGFBP5 E/ER Repressed Repressed 3.11 2.23 0.48 0.40 0.41
203287_at LAD1 E/ER Repressed Induced 1.70 1.86 1.79 1.81 2.20
216641_s_at LAD1 E/ER Repressed Induced 1.72 1.94 1.65 1.56 2.21
218574_s_at LMCD1 E/ER Repressed Induced 3.47 1.60 1.58 1.64 2.44
209679_s_at LOC57228 E/ER Repressed Induced 3.49 2.47 1.82 1.73 2.17
209373_at MALL E/ER Repressed Induced 7.87 5.99 2.21 3.06 4.35
211026_s_at MGLL E/ER Repressed Induced 2.52 2.78 3.26 2.66 4.96
217996_at PHLDA1 E/ER Repressed Induced 2.80 3.15 1.67 3.40 6.33
204284_at PPP1R3C E/ER Repressed Repressed 3.24 2.66 0.41 0.27 0.18
212636_at QKI E/ER Repressed Repressed 8.56 5.16 0.60 0.62 0.44
219562_at RAB26 E/ER Repressed Repressed 1.99 3.66 0.62 0.59 0.64
215321_at RPIB9 E/ER Repressed Repressed 1.72 1.88 0.66 0.46 0.56
213413_at SBLF E/ER Repressed Repressed 6.25 3.13 0.52 0.51 0.53
220979_s_at ST6GALNAC5 E/ER Repressed Repressed 2.87 1.55 0.64 0.61 0.66
205547_s_at TAGLN E/ER Repressed Induced 2.67 4.49 4.18 3.94 8.73
201506_at TGFBI E/ER Repressed Induced 4.45 2.24 1.63 2.11 2.81
218368_s_at TNFRSF12A E/ER Repressed Induced 1.91 1.61 1.74 2.14 2.31
218856_at TNFRSF21 E/ER Repressed Induced 4.72 2.65 1.69 4.21 5.40
214581_x_at TNFRSF21 E/ER Repressed Induced 5.81 3.41 2.08 5.43 6.63
216920_s_at TRGC2///
TRGV9///
LOC442532///
LOC442670///
TARP
E/ER Repressed Repressed 2.08 1.61 0.63 0.53 0.49
215806_x_at TRGC2///
TRGV9///
LOC442532///
LOC442670///
TARP
E/ER Repressed Repressed 2.44 1.62 0.65 0.59 0.52
E, estrogen; ER, estrogen receptor
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the prognostic value of the Ox-E/ER index appeared to be
slightly better than the Figure 5b Kaplan-Meier DSS curve
separation achieved using PR status to dichotomize the ER-
positive cases (log-rank, P = 0.009).
Discussion
As found over-expressed in human breast cancer cells and tar-
geted by all forms of endocrine therapy, the zinc finger tran-
scription factor ER is sensitive to either reversible or
irreversible impairment after even brief exposures to various
forms of oxidative stress [18]. Although there have been a
number of gene expression studies attempting to identify the
suite of estrogen responsive genes expressed in ER-positive
human breast cancers [29,47-50], none have yet asked what
subset of these estrogen responsive genes are also suscepti-
ble to modulation by oxidative stress. To address this question,
we performed gene expression microarry studies on the model
ER-positive breast cancer cell line MCF7, subjected to either
estrogen deprivation or ER-α knockdown, in order to identify a
comprehensive set of genes responsive to loss of ER function
and sensitive to oxidant stress. Modulation of oxidative stress
was accomplished by short-term (8 hours) exposure to one of
three different chemical oxidants, each given at a
predetermined titre associated with more than 50% loss of
intracellular ER transcriptional activity (assayed by transient
transfection of on ER element-luciferase reporter gene) with-
out significant loss of ER content or cell viability. Despite the
chemical differences between the thiol-specific reactant
diamide, the redox-cycling quinone menadione (vitamin K3),
and ROS-producing hydrogen peroxide, each of these oxi-
dants has been shown to attack zinc-binding cysteine residues
within the ER DNA-binding domain, preventing ER dimeriza-
tion and direct DNA binding [51,52]. By comparing the differ-
entially expressed genes between control and treatment
conditions, we identified 891 estrogen/ER-regulated probes
containing a core set of 75 probes (62 unique genes) that
were responsive to all three chemical oxidants; these 62 core
genes constituted our newly defined Ox-E/ER gene signature.
An alternative Ox' signature was experimentally determined by
Figure 4
Correlation between Ox-E/ER expression index and clinical parameters in a set of 394 ER-positive breast tumors Correlation between Ox-E/ER expression index and clinical parameters in a set of 394 ER-positive breast tumors. (a) Scatter-plot of progesterone 
receptor (PR) expression levels versus Ox-E/ER index values. Line denotes the linear regression fit of the Ox-E/ER index to PR gene expression. (b) 
Scatter-plot of age versus Ox-E/ER index. Line denotes the linear regression fit of the index to age. (c) Box plot of the Ox-E/ER index versus tumor 
grade. Significant differences in Ox-E/ER index with respect to grade are denoted with symbols (# and †; t-test, P < 0.05). Pearson correlations 
between the index and grade are also shown. (d) Box plot of the Ox-E/ER index versus ERBB2 tumor status, determined as described in Materials 
and methods. Pearson correlations between the index and ERBB2 status are also shown. *Statistically significant differences in Ox-E/ER index with 
ERBB2 status (t-test, P < 0.05). ER, estrogen receptor; Ox-E/ER, oxidant-sensitive estrogen/ER gene signature.Available online http://breast-cancer-research.com/content/10/4/R61
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oxidant exposure of MCF7 cells following knockdown of ER-α,
from which an alternate Ox'-E/ER signature was derived.
The 891 estrogen/ER-regulated probes exhibited only a 30%
overlap with genes previously described as responsive to
estrogen stimulation in the same MCF7 cell line model, using
the same basic microarray assay platform [29]. Although gene
expression changes due to estrogen deprivation have been
evaluated in the context of hormone therapy [53-55], neither
the effects of estrogen/ER withdrawal nor any comparison of
estrogen/ER withdrawal with estrogen-stimulated genes has
been reported. False discovery might account for a small frac-
tion of this discrepancy, but the magnitude of difference
between the estrogen/ER-responsive gene set identified here
and the estrogen-inducible gene set identified previously [29]
suggests that estrogen withdrawal and ER loss of function are
not entirely reciprocal conditions relative to estrogen
stimulation.
Because oxidant-induced loss of ER DNA-binding might not
impair all forms of gene regulation by ER (including co-activa-
tion of other promoter-bound transcription factor complexes
like activator protein-1 and CREB1 [cAMP response element-
binding protein 1]), it is notable that 24 out of 27 estrogen/ER-
stimulated genes within the Ox-E/ER signature were
downregulated by all three oxidants. Because little is known
about estrogen/ER-induced gene suppression, in particular its
ER DNA-binding requirement, it is not too surprising that only
29 of 48 genes originally suppressed by estrogen/ER were
subsequently upregulated by the ER-inactivating oxidant treat-
ments. These observations are consistent with recent genome
surveys indicating that ER DNA-binding sites are significantly
enriched in the promoters of early estrogen upregulated genes
but not enriched in early estrogen suppressed genes [56].
Regarding gene expression differences between the three
forms of oxidative stress, the thiol-specific oxidant diamide
affected a much smaller subset of estrogen/ER-responsive
genes than the less specific oxidants hydrogen peroxide and
menadione, both of which are also known to activate kinase
pathways. Expression of PR and the estrogen-inducible
growth regulator GREB1 were suppressed by hydrogen
peroxide and menadione but not by diamide, explaining why
these well known ER-associated genes were not part of the 62
Ox-E/ER gene signature and suggesting that their suppres-
sion was in part due to oxidant-activated kinase signaling in
addition to structural changes in ER. This possibility is sup-
ported by previous evidence showing PR downregulation
without alteration in ER content or function induced by activa-
tion of the phosphoinositide-3 kinase/AKT pathway [8].
The relationships of the five gene signatures identified (E/ER,
Ox, Ox', Ox-E/ER, and Ox'-E/ER) to clinical breast cancer
cases were explored using data from 394 ER-positive primary
human breast cancers pooled from three independently pub-
lished microarray studies [33-35]. Although PR expression
was not commonly affected by all three forms of oxidant treat-
ment, GSEA revealed that oxidant suppressed genes, in par-
ticular the oxidant suppressed E/ER regulated genes
Figure 5
Disease-specific survival analysis with respect to the Ox-E/ER Index and PR status Disease-specific survival analysis with respect to the Ox-E/ER Index and PR status. (a) Kaplan-Meier plot of events among the 201 estrogen recep-
tor (ER)-positive cases with known disease-specific survival, dichotomized by high (red) or low (green) Ox-E/ER expression index based on an opti-
mal cut-point determined using an adjusted log-rank statistic. Significance of the difference in survival between groups was determined by log-rank 
analysis. (b) Kaplan-Meier plot of events among the 201 ER-positive cases with known disease-specific survival, dichotomized based on progester-
one receptor (PR) status (PR-negative: red and PR-positive: green), with significance determined by log-rank analysis. Ox-E/ER, oxidant-sensitive 
estrogen/ER gene signature.Breast Cancer Research    Vol 10 No 4    Yau and Benz 
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identified from ER over-expressing MCF7, were suppressed in
ER-positive/PR-negative tumors relative to ER-positive/PR-
positive tumors, suggesting that loss of PR expression might
be a partial surrogate for increased oxidative stress. This sug-
gestion is consistent with our earlier reported correlation
between loss of ER DNA-binding in ER-positive/PR-negative
breast cancers [20], and with the present observation that
numeric Ox-E/ER index values correlate inversely with PR tran-
script levels and tumor PR status. Recent evidence also indi-
cates that ERBB2 over-expression is associated with loss of
PR co-expression in ER-positive breast cancers [57,58].
Although suppression of oxidant-repressed genes was not
shown to be associated with ERBB2 over-expression, there
was an enrichment of oxidant-induced genes among the
ERBB2 over-expressing ER-positive breast tumors, suggest-
ing that elevated oxidative stress is associated with ERBB2
overexpression and may contribute to the loss of PR co-
expression seen in ERBB2 overexpressing ER-positive breast
cancers.
GSEA comparisons performed using other established gene
signatures demonstrated that ER-positive/PR-negative breast
cancers express significantly higher levels of proliferation
genes relative to ER-positive/PR-positive tumors. Proliferation
genes were also expressed at higher levels in the ERBB2
overexpressing breast tumors relative to ERBB2-negative
tumors. The observed associations between tumors bearing
higher proliferation and oxidative stress signatures are consist-
ent with numerous past observations that mitogenic signaling
pathways generate and require increased ROS. Quite consist-
ently, when the oxidant stress gene signatures were consid-
ered as numeric indices, these oxidant stress indices were
significantly higher in those ER-positive tumors showing
higher proliferation gene expression, including ER-positive/
PR-negative tumors.
With regard to the putative relationships between aging,
breast cancer incidence, and oxidative stress, our GSEA find-
ings were somewhat unexpected in that they demonstrated a
weak inverse relationship between oxidative stress and age at
diagnosis, suggesting a decoupling of oxidative stress from
cellular aging mechanisms that are thought to contribute to
breast cancer development. Both GSEA and the Ox-E/ER
numeric index also associated oxidative stress with breast
tumors of higher grade, a pathologic score strongly influenced
by mitotic index. The correlations between oxidative stress and
tumor proliferation provide a potential explanation for the
apparent decoupling of oxidative stress from aging and breast
cancer development, because breast tumors arising earlier in
life are known to be more proliferative [33] and to have higher
growth rates [59]. Therefore, early age onset breast cancers
are probably subject to greater oxidative stress because of
their greater proliferative activity.
Focusing on the 62-gene Ox-E/ER signature, which best cor-
related with clinical PR status in the pooled set of 394 ER-pos-
itive breast cancer tumors, Ingenuity Pathway Systems
analysis highlighted three top networks relating to cancer, cell
development, and cell motility. In accordance with studies
associating oxidative stress with kinase signaling [21,60,61],
the top scoring network contained 19 of the Ox-E/ER genes
linked through various kinases and growth factors as well as
two stress-activated transcription factors nuclear factor-κB
and CREB1 (cAMP response element-binding protein 1). Of
particular interest is this network's inclusion of TGF-β and
platelet-derived growth factor-BB, two growth factors exten-
sively evaluated for their involvement in breast cancer progres-
sion and metastasis [62-64]. A closer look at the eight Ox-E/
ER genes linked to these growth factors revealed that most
(EGR1 [65], PHLDA1 [66], IGFBP5 [67,68], TAGLN [68],
DAB2 [69], and FHL2 [70]) have been associated with breast
cancer. In particular, downregulation of IGFBP5 and upregula-
tion of TAGLN, as observed following oxidant treatment, have
been implicated in tamoxifen resistance in a mouse mammary
xenograft model [68], suggesting that components of this Ox-
E/ER signature may be clinically relevant to the variable endo-
crine responsiveness of ER-positive breast cancers.
Given that clinical studies have been unable to show why ER-
positive/PR-negative breast cancers are significantly more
resistant to tamoxifen and other hormonal therapies [4,11], our
observations linking the Ox-E/ER signature with both the ER-
positive/PR-negative clinical phenotype and a preclinical
model of tamoxifen resistance provides new insight into how
oxidative stress may contribute to the development of clinically
more aggressive forms of ER-positive breast cancers. Of the
16 Ox-E/ER genes involved in the second highest scoring net-
work identified by Ingenuity, nine show a coordinated expres-
sion pattern signifying activated TNF signaling. Because
oxidative stress is a known byproduct of TNF activation [71], it
may not be coincidental that several members of the Ox-E/ER
gene signature are downstream targets of activated TNF sign-
aling. Contained in the 11 Ox-E/ER genes that are involved in
the third network involving cell motility pathways are two
metastasis associated genes, namely MMP2 and CTNNB1 (β-
catenin). Although the cell motility pathway was the smallest of
the three Ox-E/ER gene networks identified by Ingenuity anal-
ysis, it appears to correspond to the only over-represented
molecular function linked to the Ox-E/ER gene signature by
Gene Ontology analysis in DAVID (Database for Annotation,
Visualization, and Integrated Discovery; set size > 5,
Expression Analysis Systematic Explorer score < 0.05) [72],
that of 'actin-binding' genes.
The numeric Ox-E/ER index allowed for its prognostic evalua-
tion as either a continuous variable or as a categorical param-
eter, based on an optimized cut-point determination and
dichotomization of the pooled ER-positive tumors into those
with high versus low Ox-E/ER index values. Despite its corre-Available online http://breast-cancer-research.com/content/10/4/R61
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lation with proliferation genes, loss of PR expression, ERBB2
over-expression, and higher tumor grade, the Ox-E/ER index
as a continuous variable did not achieve (although it exhibited
a trend toward) significance with respect to DSS. However,
when an optimized cut-point for the index value was deter-
mined (based on a maximized adjusted log-rank statistic) to
achieve the greatest possible separation between the Kaplan-
Meier DSS curves, the Ox-E/ER index proved capable of
dichotomizing the pooled ER-positive breast cancers into two
groups whose significant difference in survival exceeded that
achieved by PR status alone. This suggests that oxidative
stress, and its effects on E/ER signaling, contributes to the
development of an aggressive subset of primary ER-positive
breast cancers.
Conclusion
Using a well established cell line model of ER-positive human
breast cancer subjected to conditions simulating loss of ER
function and oxidative stress, we identified a signature set of
62 unique Ox-E/ER genes, 46 of which are connected within
networks associated with increased oxidant signaling, cancer
growth factor, and cell motility pathways. Clinical evaluation of
this Ox-E/ER signature, as well as alternative oxidant signa-
tures, was performed using a pooled dataset of 394 ER-posi-
tive breast cancer cases for which microarray data were
available. Despite reports attributing organismal aging to
accumulated oxidative stress, there was no evidence to indi-
cate excess oxidative stress in breast cancers arising later in
life. To the contrary, the present study indicates that breast
cancers showing greater proliferative activity, such as those
arising earlier in life, exhibit the greatest oxidative stress. The
62-gene Ox-E/ER signature inversely correlated with tumor
PR status and mRNA levels, and was positively associated
with ERBB2 over-expression. An optimized Ox-E/ER index
cut-point was shown to be capable of dichotomizing the
pooled ER-positive breast cancer cases into subgroups
whose significant difference in DSS exceeded that achieved
by PR dichotomization. Thus, these basic and clinical findings
suggest that oxidative stress may contribute to the develop-
ment of an aggressive subset of primary ER-positive breast
cancers, including those exhibiting the ER-positive/PR-nega-
tive clinical phenotype.
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